PT MEDIKALOKA HERMINA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 IDR | +0.46% |
|
-6.03% | -26.85% |
| Sales 2024 * | 6,567B 407M 33.79B | Sales 2025 * | 7,230B 448M 37.2B | Capitalization | 16,117B 999M 82.94B |
|---|---|---|---|---|---|
| Net income 2024 * | 565B 35.03M 2.91B | Net income 2025 * | 695B 43.09M 3.58B | EV / Sales 2024 * | 2.62 x |
| Net Debt 2024 * | 1,080B 66.97M 5.56B | Net Debt 2025 * | 753B 46.71M 3.88B | EV / Sales 2025 * | 2.33 x |
| P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
23.1
x | Employees | 16,258 |
| Yield 2024 * |
0.98% | Yield 2025 * |
1.22% | Free-Float | 51.96% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.46% | ||
| 1 week | -6.03% | ||
| Current month | -7.23% | ||
| 1 month | -14.17% | ||
| 3 months | -18.35% | ||
| 6 months | -28.05% | ||
| Current year | -26.85% |
1 week
1 060.00
1 170.00
1 month
1 060.001 250.00
Current year
1 060.001 500.00
1 year
1 060.001 575.00
3 years
872.001 800.00
5 years
370.001 800.00
10 years
370.001 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hermina Hasmoro
CEO | Chief Executive Officer | 81 | 01/91/01 |
| Director of Finance/CFO | 42 | - | |
Yuyun Gunaedi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gidion Hasan
BRD | Director/Board Member | 52 | 25/22/25 |
| Director/Board Member | 63 | 01/17/01 | |
| Director/Board Member | 53 | 17/18/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,090 | +0.46% | 8,739,500 |
| 25/24/25 | 1,085 | -5.65% | 10,987,400 |
| 24/24/24 | 1,150 | +4.07% | 5,665,900 |
| 23/24/23 | 1,105 | -1.78% | 2,265,300 |
| 22/24/22 | 1,125 | -3.02% | 7,706,900 |
End-of-day quote INDONESIA S.E., April 26, 2024
More quotes
PT Medikaloka Hermina Tbk is an Indonesia-based company, which is engaged in offering general hospital services. The Company is focused on providing services for BPJS patients to support government program in Indonesia. The Companyâs services include hospitals, specialties, and featured services. The Companyâs hospitals include Hermina Arcamanik, Hermina Balikpapan, Hermina Banyumanik, Hermina Bekasi, Hermina Bitung, Hermina Bogor, Hermina Ciledug, Hermina Cilegon and Hermina Ciputat. In specialties service, the Company provides anatomical pathology, andrology, anesthesiology, cardiology, clinical microbiology, clinical pathology, dentistry, dermatology and venereology, dietetics, emergency medicine, forensic and medicolegal, internal medicine, medical acupuncture, neurology, and surgery. Its subsidiaries include PT Medikaloka Internusa (M Internusa), PT Medikaloka Sejahtera (M Sejahtera), PT Medikaloka Husada (M Husada), PT Medikaloka Daan Mogot and PT Medikaloka Pasteur (M Pasteur).
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1,090
IDR
Average target price
1,680
IDR
Spread / Average Target
+54.13%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.85% | 993M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- HEAL Stock
